Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $132 Price Target

Benzinga Newsdesk www.benzinga.com Negative 92.7%

Neg 92.7% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $132 price target.